Health Blueprint

Back to Longevity News

News summary

BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates

Source: BioAge Labs • Published: 05 Nov 2026, 21:30

Summarized by Masters of Longevity from BioAge Labs.

BioAge dosed the first participant in a Phase 2 diabetic macular edema trial of BGE-102.

BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
Key Takeaways
  • BGE-102 is in a Phase 2 DME trial with topline 2027 expectations.
  • QUELL-CV was fully enrolled and will report hsCRP dose-response in Q4 2026.
  • An APJ agonist program is advancing and aims for an IND by year-end 2026.
Read the full article at BioAge Labs ↗

Continue exploring

Recommended MoL Picks

MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickMelatonin and Heart Failure: What the Evidence Actually ShowsA 2025 study linked melatonin use with heart failure. A 2026 analysis found no significant association. Their different designs explain why the question remains open.